Inside Oncology Drug Development: Overcoming Resistance with Science

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that resistance often leads to disease relapse, severely impacting patient outcomes and quality of life.

As we develop increasingly precise and powerful cancer therapies, how can we anticipate and overcome the inevitable challenge of drug resistance?

In this episode of Crowncast, host Jonny McMichael, VP of Client Experience & Enablement at Crown BioScience, speaks with Enrico Pesenti, the company’s Executive Director of Client Engagement. Together, they explore the evolving landscape of oncology drug resistance—unpacking the biological mechanisms behind it, the impact on patient care, and the technological breakthroughs helping researchers counter it.

Main Points:

  • Resistance in cancer therapy emerges through both genetic mutations and adaptive, non-genetic mechanisms, presenting a dynamic challenge for drug developers.

  • New technologies—such as single-cell multi-omics, spatial transcriptomics, and CRISPR gene editing—are enabling deeper understanding and more precise modeling of resistance pathways.

  • Translational models like organoids and patient-derived xenografts, combined with AI and machine learning, are helping design better, more personalized therapeutic strategies.

Enrico Pesenti brings over two decades of experience in oncology research and drug development. He previously held leadership roles at Pharmacia and Nerviano and served as CEO of Accelera, a regulatory CRO in Italy. At Crown BioScience, he leads scientific engagement, drawing on deep expertise in pharmacology and personalized cancer therapies.

Recent Episodes

The U.S. healthcare system is at a crossroads — facing rising costs, limited competition, and a widening gap between innovation and accessibility. According to projections from the Centers for Medicare & Medicaid Services (CMS), national health spending is expected to grow faster than the overall economy over the next decade — about 5.8% per year…

Hospitals today are juggling tighter budgets, shifting regulations, and increasingly savvy patients—all while trying to keep financial operations running smoothly. That pressure has made the revenue cycle a powerful lever for innovation. The spread of artificial intelligence (AI) and automation is no longer experimental; it’s reshaping how health systems manage billing, reimbursement, and patient engagement….

Hospitals today are fighting a two-front battle — one against increasingly sophisticated payers armed with automation and AI, and another to meet patients’ rising expectations for clarity and convenience. A recent joint study by Knowtion Health and the Healthcare Financial Management Association found that nearly one in two revenue cycle executives now identify payer denials…